Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...
12h
Zacks.com on MSNPCRX Doses First Patient in Phase II PCRX-201 Gene Therapy StudyPacira BioSciences PCRX announced that it has dosed the first patient in a mid-stage study of pipeline candidate PCRX-201 ...
Here is our list of the 11 Best Gene Therapy Stocks to Buy According to Analysts.
Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...
1d
Pharmaceutical Technology on MSNAtsena closes $150m in Series C round to progress gene therapyAtsena Therapeutics has completed an oversubscribed Series C financing round, raising $150m to support the advancement of ...
Marks’ resignation leaves the field without a regulator many view as “integral” to its progress over the last decade.
The $150 million will also go toward Atsena’s preclinical pipeline and expand the use of the biotech’s spreading AAV.SPR ...
Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...
In response to a request from the European Medicines Agency (EMA) following the death of a 16-year-old patient in the U.S., ...
Out of the shadows, new CDMO Artis BioSolutions has decloaked on a mission to tackle the tricky production process for ...
None of the cell and gene therapies that reached the final regulatory submission stage were rejected by the FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results